Lung cancer Posts - Page 2 of 41 on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Can specialized imaging techniques improve how chemo-radiotherapy is administered in locally advanced non-small cell lung cancer?

Posted by on Apr 21, 2020 in Lung cancer | 0 comments

In a nutshell This study set out to compare conventional-dose chemoradiotherapy (CRT) to reduced CRT based on 18F-FDG PET in locally advanced non-small cell lung cancer (NSCLC). The investigators found that 18F-FDG PET-based CRT improved tumor control without increasing side effects in these patients.  Some background NSCLC accounts for...

Read More

Can antibiotics and proton pump inhibitors alter the effectiveness of treatment for patients with non-small cell lung cancer?

Posted by on Apr 21, 2020 in Lung cancer | 0 comments

In a nutshell This study examined the effects of antibiotics or proton pump inhibitor (PPI) drugs on treatment for patients with non-small cell lung cancer (NSCLC). The authors found that both antibiotics and PPIs reduced the effectiveness of biological therapy but not chemotherapy. Some background Not all patients with NSCLC respond to...

Read More

What gut-related side effects do immunotherapy drugs and chemotherapy cause patients with cancer?

Posted by on Apr 14, 2020 in Lung cancer | 0 comments

In a nutshell This study examined if certain immunotherapy drugs increased the risk of developing side effects in the gut in patients with cancer also receiving chemotherapy. The results showed that immunotherapy drugs increased the risks of developing gut-related side effects compared to chemotherapy alone. Some background Immunotherapy drugs that...

Read More

Do biological drugs work better alone or in combination with other drugs for patients with advanced non-small cell lung cancer who previously received treatment?

Posted by on Apr 7, 2020 in Lung cancer | 0 comments

In a nutshell This study compared if anti-PD-1 biological drugs were more effective alone or when used with other drugs to treat patients with advanced non-small cell lung cancer who had previously received treatment. The results showed that the combination of anti-PD-1 and other drugs such as chemotherapy improved patients’ survival more than...

Read More

Does immune cell boosting drug G-CSF reduce the effects of chemotherapy in different cancers?

Posted by on Apr 5, 2020 in Lung cancer | 0 comments

In a nutshell This study examined the effects of granulocyte colony-stimulating factor (G-CSF) given as a preventative measure in patients with high- and medium-risk cancer receiving chemotherapy. The results showed that preventative G-CSF allowed more patients to complete chemotherapy treatment and lowered patients’ chances of developing secondary...

Read More

What are the long-term effects of treatment with a biological drug versus chemotherapy for patients with advanced non-small cell lung carcinoma?

Posted by on Mar 29, 2020 in Lung cancer | 0 comments

In a nutshell This study compared the long-term effects of biological drug pembrolizumab (Keytruda) with chemotherapy drug docetaxel (Taxotere) in patients with advanced non-small cell lung carcinoma (NSCLC). The study found that pembrolizumab increased survival and had fewer side effects than docetaxel. Some background Patients with advanced...

Read More

Side effects of immunotherapy vs chemotherapy for the treatment of lung cancer

Posted by on Feb 29, 2020 in Lung cancer | 0 comments

In a nutshell This study wanted to compare the side effects of immunotherapy and those of chemotherapy for lung cancer. The study found that immunotherapy was associated with fewer side effects than treatment with chemotherapy. Some background Standard treatment for cancer included chemotherapies. These include drugs that attack and kill cancer cells....

Read More

Treating advanced and reoccurring small cell lung cancer with pembrolizumab

Posted by on Jan 26, 2020 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if pembrolizumab (Keytruda) treatment works in patients with small-cell lung cancer who have received at least two other types of cancer treatment before. The study found that treatment with pembrolizumab was effective and well tolerated in these patients. Some background Small-cell lung cancer (SCLC)...

Read More

Durvalumab after chemoradiotherapy for non-small cell lung cancer: analysis from the patients’ perspective

Posted by on Dec 23, 2019 in Lung cancer | 0 comments

In a nutshell This study evaluated the patient-reported outcomes after treatment with durvalumab (Imfinzi) for stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed. This study concluded that durvalumab did not affect the quality of life of these patients. Some background NSCLC is the most common form of lung cancer...

Read More

Adding ramucirumab to erlotinib treatment for patients with advanced non-small cell lung cancer with EGFR mutations

Posted by on Dec 20, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if using two kinds of medication together worked better than only one medication to treat advanced non-small cell lung cancer that has not been treated before. The study found that using ramucirumab (Cyramza) with erlotinib (Tarceva) was better than using erlotinib alone. Some background There are a number...

Read More